ArticleJournal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi2020
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
Article in Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 5 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.Drug design, development and therapy · 2022Pooled it
- Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies.Clinical pharmacology and therapeutics · 2021Pooled it
- An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.Journal of infection and public health · 2020Pooled it
- SARS-CoV-2 detection, viral load and infectivity over the course of an infection.The Journal of infection · 2020Pooled it
- Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis.Indian journal of pharmacologyPooled it
- Trial
- Ordinary differential equation models of SARS-CoV-2 replication dynamics and antiviral drug efficacies.Npj viruses · 2026Review
- Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies.Molecules (Basel, Switzerland) · 2024Review
- Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review.Clinical pharmacology : advances and applications · 2024Review
- Identification of human genetic variants modulating the course of COVID-19 infection with importance in other viral infections.Frontiers in genetics · 2023Article
- COVID-19 patient characteristics and time to viral clearance: A retrospective observational study in a multiethnic population (United Arab Emirates).Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022Observational
- Duration of SARS-CoV-2 RNA positivity from various specimens and clinical characteristics in patients with COVID-19: a systematic review and meta-analysis.Inflammation and regeneration · 2022Review
- Risk factors for prolonged virus shedding of respiratory tract and fecal in adults with severe acute respiratory syndrome coronavirus-2 infection.Journal of clinical laboratory analysis · 2021Article
- Clinical validation of an automated reverse transcription-insulated isothermal PCR assay for the detection of severe acute respiratory syndrome coronavirus 2.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2021Article
- Clinical Management of COVID-19: A Review of Pharmacological Treatment Options.Pharmaceuticals (Basel, Switzerland) · 2021Review
- SARS-CoV-2: Targeted managements and vaccine development.Cytokine & growth factor reviews · 2021Review
- Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments.International journal of clinical practice · 2021Review
- Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.Biomedical journal · 2021Review
- A brief review on potential application of mesenchymal stem cell and secretome in combating mortality and morbidity in COVID-19 patients.Biomedical journal · 2021Review
- Risk management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2.Journal of infection and public health · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increase of Ct values was 0.9 per day in 2 cases of COVID-19 treated with lopinavir/ritonavir (LPV/r), an increase was 1.0 per day in 3 cases without LPV/r through illness day 1-10, indicating that LPV/r did not shorten the duration of SARS CoV-2 shedding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.